Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products Co., Ltd. (上海莱士血液制品股份有限公司), commonly known as Shanghai RAAS, is a China-based biopharmaceutical company focused on the research, development, production, and sale of plasma-derived products. Founded in 1988 and headquartered in Shanghai, the company has grown into one of the leading players in China's blood products industry. Its portfolio includes human serum albumin, intravenous immunoglobulin (IVIG), coagulation factor VIII, and other plasma-derived therapies used in critical care, immunology, and hematology. Shanghai RAAS is listed on the Shenzhen Stock Exchange under the ticker 002252. The company operates plasma collection centers across China and invests in R&D to expand its product pipeline. It has also pursued international partnerships and acquisitions to strengthen its technological capabilities and market position. In recent years, Shanghai RAAS has emphasized quality control and safety in plasma collection and manufacturing, aligning with global standards. The company's products are used in hospitals and clinics throughout China, addressing a range of medical conditions including liver disease, immune deficiencies, and bleeding disorders. As a key player in the Chinese plasma fractionation sector, Shanghai RAAS continues to navigate regulatory changes and market dynamics while expanding its production capacity and product offerings.

Shanghai RAAS Blood Products Co., Ltd. was established in 1988 in Shanghai, China, as a blood products enterprise. Over the decades, it expanded its plasma collection network and product portfolio, becoming one of the first Chinese companies to produce plasma-derived therapies at scale. The company was listed on the Shenzhen Stock Exchange, using capital markets to fund capacity expansion and R&D. In the 2010s, Shanghai RAAS pursued strategic acquisitions and partnerships to enhance its technological capabilities. It invested in plasma collection centers across multiple provinces, securing a stable supply of raw plasma. The company also focused on improving manufacturing standards to meet stringent regulatory requirements. In recent years, Shanghai RAAS has continued to grow its product offerings, including albumin, immunoglobulins, and coagulation factors, and has explored international collaborations. Despite industry challenges such as plasma supply constraints and regulatory changes, the company remains a key player in China's blood products sector.

• 1988

  Company founded in Shanghai, China.

• Listed on the Shenzhen Stock Exchange (ticker 002252).

Leading Chinese plasma fractionation company with a focus on quality and safety.

• Human serum albumin

  Plasma-derived albumin used for volume expansion and other indications.

• Intravenous immunoglobulin (IVIG)

  Immunoglobulin therapy for immune deficiencies and autoimmune conditions.

• Coagulation factor VIII

  Clotting factor used in hemophilia A treatment.

• 2026.10

  Shanghai RAAS adjusts second-phase employee stock ownership plan[1]上海莱士调整第二期员工持股计划cfi.net.cn

  Shanghai RAAS Blood Products Co., Ltd. (002252) adjusted its second-phase 2026 employee stock ownership plan and disclosed a revised draft, for which Beijing Zhong Lun (Shanghai) Law Firm issued a legal opinion dated October 2026. The revision lowers the planned fundraising cap to 65.4522 million yuan, lowers the planned share scale to up to 23.21 million Shanghai RAAS A-shares sourced from the company's repurchase account, and lowers the expected initial number of participants to no more than 128. Because the company's 2025 annual profit distribution was implemented on June 24, 2026 and the repurchased shares had not yet been transferred to the plan, the purchase price for plan participants was adjusted from 2.85 yuan to 2.82 yuan per share. The revised plan may be financed through asset-management or trust plans funded by financial institutions with a leverage ratio not exceeding 1:1, and may engage external professional institutions to provide asset-management services.

Read more

1. 1上海莱士调整第二期员工持股计划cfi.net.cn